• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?

作者信息

Monzo Luca, Ferrari Ilaria, Cicogna Francesco, Tota Claudia, Calò Leonardo

机构信息

Department of Cardiology, Policlinico Casilino.

Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University, Rome, RomeItaly.

出版信息

J Cardiovasc Med (Hagerstown). 2022 Aug 1;23(8):567-569. doi: 10.2459/JCM.0000000000001331.

DOI:10.2459/JCM.0000000000001331
PMID:35901508
Abstract
摘要

相似文献

1
What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?射血分数保留的心力衰竭患者中，有多少比例适合使用恩格列净？
J Cardiovasc Med (Hagerstown). 2022 Aug 1;23(8):567-569. doi: 10.2459/JCM.0000000000001331.
2
Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial".格伦达等人就文章《恩格列净对射血分数保留的心力衰竭患者心力衰竭事件恶化的影响：EMPEROR-Preserved试验》的来信
Circulation. 2022 Apr 19;145(16):e839-e840. doi: 10.1161/CIRCULATIONAHA.121.057530. Epub 2022 Apr 18.
3
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
4
[Empagliflozin in the treatment of heart failure with preserved ejection fraction].
Inn Med (Heidelb). 2022 Jul;63(7):808-810. doi: 10.1007/s00108-022-01345-5. Epub 2022 May 17.
5
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.恩格列净、健康状况和射血分数保留的心力衰竭患者的生活质量：EMPEROR-Preserved 试验。
Circulation. 2022 Jan 18;145(3):184-193. doi: 10.1161/CIRCULATIONAHA.121.057812. Epub 2021 Nov 15.
6
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.恩格列净作为附加疗法对因急性失代偿性心力衰竭住院的糖尿病患者的充血和肾功能的影响：一项前瞻性随机对照研究。
Circ Heart Fail. 2021 Mar;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Epub 2021 Mar 5.
7
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.DAPA-HF试验标志着射血分数降低的心力衰竭治疗新时代的开始。
Cardiovasc Res. 2020 Jan 1;116(1):e8-e10. doi: 10.1093/cvr/cvz328.
8
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".辛格等人就文章《恩格列净对2型糖尿病或糖尿病前期且射血分数降低的心力衰竭患者左心室容积的影响（SUGAR-DM-HF）》所写的信。
Circulation. 2021 Jul 20;144(3):e38-e39. doi: 10.1161/CIRCULATIONAHA.120.053057. Epub 2021 Jul 19.
9
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction.简要研究：恩格列净用于射血分数保留的心力衰竭患者。
Clin Med (Lond). 2022 Jan;22(1):75-76. doi: 10.7861/clinmed.rib.22.1.1.
10
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.恩格列净对射血分数保留的心力衰竭女性和男性患者的影响。
Circulation. 2022 Oct 4;146(14):1046-1055. doi: 10.1161/CIRCULATIONAHA.122.059755. Epub 2022 Sep 13.

引用本文的文献

1
Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians.心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：临床医生基于证据的最新实用指南
Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C309-C315. doi: 10.1093/eurheartjsupp/suad055. eCollection 2023 May.
2
Treating chronic kidney disease to reduce cardiovascular risk.治疗慢性肾脏病以降低心血管风险。
Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B50-B54. doi: 10.1093/eurheartjsupp/suad067. eCollection 2023 Apr.
3
The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target.
心脏衰竭表型中心外膜脂肪组织的不同途径：从病理生理学到治疗靶点。
Int J Mol Sci. 2023 Apr 6;24(7):6838. doi: 10.3390/ijms24076838.
4
New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy.心肾综合征的新认识：从生物标志物到治疗。
Int J Mol Sci. 2023 Mar 7;24(6):5089. doi: 10.3390/ijms24065089.
5
Sodium-glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome.用于治疗心肾综合征的钠-葡萄糖协同转运蛋白2抑制剂
Eur Heart J Suppl. 2022 Nov 12;24(Suppl I):I68-I71. doi: 10.1093/eurheartjsupp/suac101. eCollection 2022 Nov.